¿ÀÅ°Ææ¾×(ÄÉÅäÇÁ·ÎÆæ¸®½Å) OKIFEN SOLN
Àü¹®ÀǾàǰ | »èÁ¦
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
ƯÀ¯ÀÇ Çâ°ú ¸ÀÀ» °¡Áø ³ì»öÀÇ Åõ¸íÇÑ ¾×Á¦
Á¦Á¶È¸»ç
Çö´ë¾àǰ(ÁÖ)
ÆÇ¸Åȸ»ç
Çö´ë¾àǰ(ÁÖ)
Çã°¡Á¤º¸
ÃëÇÏ
(2020.04.01)
BIT ¾àÈ¿ºÐ·ù
±âŸ ±¸°¿ë¾à
º¹ÁöºÎºÐ·ù
231[Ä¡°ú±¸°¿ë¾à ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
642000900[A30603911] \0 ¿ø/1ml(2016.10.01) (ÇöÀç¾à°¡) \18 ¿ø/1ml(2014.02.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Ketoprofen / M02AA10
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
±Û¸®¼¼¸° ,
¹ÚÇÏÇâ ,
»èÄ«¸°³ªÆ®·ý ,
¼ö»êȳªÆ®·ý ,
½Ä¾àûÀÎÁ¤Å¸¸£»ö¼Ò ,
¿¡Åº¿Ã ,
¿¤ ¸àÅç ,
ÀλêÀ̼ö¼Ò³ªÆ®·ý ,
Á¤Á¦¼ö ,
ÆÄ¶ó¿Á½Ã¾È½ÄÇâ»ê¸ÞÄ¥
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
642000900[A30603911]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml(2016.10.01) (ÇöÀç¾à°¡)
\18 ¿ø/1ml(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
ƯÀ¯ÀÇ Çâ°ú ¸ÀÀ» °¡Áø ³ì»öÀÇ Åõ¸íÇÑ ¾×Á¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
150¹Ð¸®¸®ÅÍ
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
500¹Ð¸®¸®ÅÍ
1 °³
8806420009003
8806420009027
150¹Ð¸®¸®ÅÍ
1 °³
8806420009003
8806420009010
ÁÖ¼ººÐÄÚµå
179803CLQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806420009003
º¸°ü¹æ¹ý
Â÷±¤±â¹Ð¿ë±â, ½Ç¿Â(1-30¡É)º¸°ü
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ¿¡ ÀÇÇÑ ¿°ÁõÀÇ ¿ÏÈ : Ä¡Àº¿°, ±¸³»¿°, Àεο° ¹ßÄ¡Àü․ÈÄ
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ȸ 10mL 1ÀÏ 2ȸ 100mLÀÇ ¹°¿¡ Èñ¼®ÇÏ¿© ÀÔ¾ÈÀ» Çó±¸¾î ³»°Å³ª °¡±ÛÇÑ ÈÄ
¹ñ´Â´Ù.
±Ý±â
1) ÀÌ ¾à ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦¿¡ ¾Ë·¹¸£±â ¹ÝÀÀ (õ½Ä, µÎµå·¯±â ¶Ç´Â ºñ¿°) ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
3) 6¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ
½ÅÁßÅõ¿©
1) ±â°üÁö õ½Ä ȯÀÚ(õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù)
2) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
3) °í·ÉÀÚ
ÀÌ»ó¹ÝÀÀ
ÀÌ ¾à »ç¿ë ÈÄ ±¹¼ÒÁö°¢°¨Åð, ±¹¼ÒÁö°¢Âø¿À, ±¸°ÀÛ¿°¨, ±¸°¥, Àεο° µîÀÇ Áõ»óÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
ÀϹÝÀû ÁÖÀÇ
1) ¼Ò¿°ÁøÅëÁ¦¿¡ ÀÇÇÑ Ä¡·á´Â ¿øÀοä¹ýÀÌ ¾Æ´Ñ ´ëÁõ¿ä¹ýÀÓ¿¡ À¯ÀÇÇÑ´Ù.
2) ±¹¼Ò Àû¿ëÇÏ´Â ¾à¹°Àº (ƯÈ÷, Àå±â°£ »ç¿ë½Ã) °ú¹ÎÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù. °ú¹ÎÁõÀÌ ³ªÅ¸³¯ °æ¿ì, Áï½Ã »ç¿ëÀ» Áß´ÜÇϰí ÀûÀýÇÑ Ä¡·á¸¦ ½Ç½ÃÇØ¾ß ÇÑ´Ù.
3) ´Ù¸¥ ¼Ò¿°ÁøÅëÁ¦¿ÍÀÇ º´¿ëÀº ÇÇÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
4) 1ÁÖÀÏ Á¤µµ »ç¿ëÇÏ°íµµ Áõ»óÀÇ °³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù.
»óÈ£ÀÛ¿ë
1) ÇöÀç ´Ù¸¥ ¾à°úÀÇ »óÈ£ÀÛ¿ëÀº ¿¬±¸µÈ ¹Ù ¾ø´Ù.
2) Àå±â°£ »ç¿ë½Ã ¶Ç´Â °ú·® Åõ¿©½Ã Èí¼öµÈ ÄÉÅäÇÁ·ÎÆæ°ú Ç÷Áß ´Ü¹é°ú °áÇÕÇÑ ´Ù¸¥ ¾à¹°°£¿¡ °æÀïÀÌ ÀϾ ¼ö ÀÖ´Ù.
ÀӺο¡ ´ëÇÑ Åõ¿©
[ÀӺαݱ⠼ººÐ Á¶È¸]
´Ù¸¥ ºñ½ºÅ×·ÎÀ̵强 ÁøÅë¼Ò¿°Á¦¿Í ¸¶Âù°¡Áö·Î ÀÌ ¾àÀº ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× ¼öÀ¯ºÎ¿¡ ´ëÇØ¼´Â »ç¿ëÀ» ÇÇÇÑ´Ù.
¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿©
´Ù¸¥ ºñ½ºÅ×·ÎÀ̵强 ÁøÅë¼Ò¿°Á¦¿Í ¸¶Âù°¡Áö·Î ÀÌ ¾àÀº ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× ¼öÀ¯ºÎ¿¡ ´ëÇØ¼´Â »ç¿ëÀ» ÇÇÇÑ´Ù.
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© :
¼Ò¾Æ¿¡ ´ëÇÑ À¯È¿¼º ¹× ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù.
°í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿© :
°í·ÉÀÚ´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³ª±â ½¬¿ì¹Ç·Î ¼Ò·®¿¡¼ Åõ¿©¸¦ ½ÃÀÛÇÏ´Â µî ȯÀÚÀÇ »óŸ¦ °üÂûÇÏ¸é¼ ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
°ú·®Åõ¿© ¹× óġ
ÀÌ ¾àÀ» ºÎÀûÀýÇÏ°Ô ¶Ç´Â °ú·® »ç¿ëÇÑ °æ¿ì¿¡´Â ºñ½ºÅ×·ÎÀ̵强 ÁøÅë¼Ò¿°Á¦ Áßµ¶½Ã¿¡ ÇÊ¿äÇÑ ÀûÀýÇÑ Ã³Ä¡¸¦ ¼öÇàÇÑ´Ù.
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
Â÷±¤±â¹Ð¿ë±â, ½Ç¿Â(1-30¡É)º¸°ü
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
µ¶¼ºÁ¤º¸
Ketoprofen ¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action
Ketoprofen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Ketoprofen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis, and leukotriene synthesis, to have antibrady-kinin activity, as well as to have lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Pharmacology
Ketoprofen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ketoprofen is a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, that is thought to be associated with the inhibition of prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
Metabolism
Ketoprofen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
Absorption
Ketoprofen¿¡ ´ëÇÑ Absorption Á¤º¸ Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
Pharmacokinetics
Ketoprofen lysinateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
´ë»ç : °£´ë»ç
¹Ý°¨±â : 1-4 ½Ã°£
Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 0.5-2 ½Ã°£
¼Ò½Ç : ½Å¹è¼³(60-75%), ÁÖ·Î glucuronide Æ÷ÇÕü·Î ¹è¼³µÊ
Toxicity
Ketoprofen¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 =62.4 mg/kg (rat, oral) Adverse effects from overdose include breathing difficulty, coma, convulsions, drowsiness, high blood pressure, kidney failure, low blood pressure, nausea, sluggishness, stomach and intestinal bleeding, stomach pain, vomiting.
Drug Interactions
Ketoprofen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Alendronate Increased risk of gastric toxicityMethotrexate The NSAID increases the effect and toxicity of methotrexateCyclosporine Monitor for nephrotoxicityAnisindione The NSAID increases the anticoagulant effectAcenocoumarol The NSAID increases the anticoagulant effectDicumarol The NSAID increases the anticoagulant effectWarfarin The NSAID increases the anticoagulant effect
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Food Interaction
Ketoprofen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food to reduce irritation, avoid alcohol.
Drug Target
[Drug Target]
Description
Ketoprofen¿¡ ´ëÇÑ Description Á¤º¸ An ibuprofen-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. [PubChem]
Dosage Form
Ketoprofen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralSuppository RectalTablet, coated OralTablet, extended release Oral
Drug Category
Ketoprofen¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase Inhibitors
Smiles String Canonical
Ketoprofen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Smiles String Isomeric
Ketoprofen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@@H](C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
InChI Identifier
Ketoprofen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/f/h18H
Chemical IUPAC Name
Ketoprofen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[3-(benzoyl)phenyl]propanoic acid
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù